Nexalin Technology, Inc. Research and Development Expense
Nexalin Technology, Inc. (NXL) reported Research and Development Expense of $564.48 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Nexalin Technology, Inc. research and development expense for the quarter ending 2026-06-30 was $564.48K, a 150.02% increase year-over-year.
- Nexalin Technology, Inc. research and development expense for the quarter ending 2026-03-31 was $346.38K, a 14.74% decline year-over-year.
- Nexalin Technology, Inc. research and development expense for the quarter ending 2025-12-31 was $224.94K, a 69.49% decline year-over-year.
- Nexalin Technology, Inc. research and development expense for the quarter ending 2025-09-30 was $226.52K, a 26.86% increase year-over-year.
- Nexalin Technology, Inc. research and development expense for fiscal 2025 was $1.08M, a 9.02% decline from fiscal 2024.
- Nexalin Technology, Inc. research and development expense for fiscal 2024 was $1.19M, a 38.03% decline from fiscal 2023.
- Nexalin Technology, Inc. research and development expense for fiscal 2023 was $1.92M, a 276.09% increase from fiscal 2022.
- Nexalin Technology, Inc. research and development expense for fiscal 2022 was $511.00K, a 267.63% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $564.48K 10-Q · filed 2026-08-12 | $910.86K 10-Q · filed 2026-08-12 | $1.14M derived: sum of 3 quarters · filed 2026-08-12 | $1.36M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2026-03-31 | $346.38K 10-Q · filed 2026-05-08 | $571.32K derived: sum of 2 quarters · filed 2026-05-08 | $797.84K derived: sum of 3 quarters · filed 2026-05-08 | $1.02M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-12-31 | $224.94K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $451.46K derived: sum of 2 quarters · filed 2026-03-25 | $677.23K derived: sum of 3 quarters · filed 2026-08-12 | $1.08M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $226.52K 10-Q · filed 2025-11-14 | $452.29K derived: sum of 2 quarters · filed 2026-08-12 | $858.58K 10-Q · filed 2025-11-14 | $1.60M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-06-30 | $225.77K 10-Q · filed 2026-08-12 | $632.06K 10-Q · filed 2026-08-12 | $1.37M derived: sum of 3 quarters · filed 2026-08-12 | $1.55M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-03-31 | $406.29K 10-Q · filed 2026-05-08 | $1.14M derived: sum of 2 quarters · filed 2026-05-08 | $1.32M derived: sum of 3 quarters · filed 2026-05-08 | $1.49M derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $737.24K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $915.81K derived: sum of 2 quarters · filed 2026-03-25 | $1.09M derived: sum of 3 quarters · filed 2026-03-25 | $1.19M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $178.56K 10-Q · filed 2025-11-14 | $347.98K derived: sum of 2 quarters · filed 2025-11-14 | $453.64K 10-Q · filed 2025-11-14 | $453.64K 10-Q · filed 2024-11-08 | $533.11K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $169.41K 10-Q · filed 2025-08-06 | $169.41K 10-Q · filed 2024-08-08 | $275.08K 10-Q · filed 2025-08-06 | $354.55K derived: sum of 3 quarters · filed 2025-09-23 | $1.99M derived: sum of 4 quarters · filed 2025-09-23 | ||
| 2024-03-31 | $105.67K 10-Q · filed 2025-05-13 | $185.14K derived: sum of 2 quarters · filed 2025-09-23 | $1.82M derived: sum of 3 quarters · filed 2025-09-23 | $1.97M derived: sum of 4 quarters · filed 2025-09-23 | |||
| 2023-12-31 | $79.47K derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-09-23 | $1.72M derived: sum of 2 quarters · filed 2025-09-23 | $1.86M derived: sum of 3 quarters · filed 2025-09-23 | $1.92M 10-K/A · filed 2025-09-23 | $1.92M 10-K · filed 2024-03-27 | ||
| 2023-09-30 | $1.64M 10-Q · filed 2024-11-08 | $1.78M derived: sum of 2 quarters · filed 2024-11-08 | $1.84M 10-Q · filed 2024-11-08 | $2.21M derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2023-06-30 | $146.00K 10-Q · filed 2024-08-08 | $211.83K 10-Q · filed 2024-08-08 | $568.11K derived: sum of 3 quarters · filed 2024-08-08 | $681.73K derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $65.83K 10-Q · filed 2024-05-10 | $422.11K derived: sum of 2 quarters · filed 2024-05-10 | $535.73K derived: sum of 3 quarters · filed 2024-05-10 | $565.27K derived: sum of 4 quarters · filed 2024-05-10 | |||
| 2022-12-31 | $356.28K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $469.89K derived: sum of 2 quarters · filed 2024-03-27 | $499.44K derived: sum of 3 quarters · filed 2024-03-27 | $511.00K 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $113.62K 10-Q · filed 2023-11-13 | $143.16K derived: sum of 2 quarters · filed 2023-11-13 | $154.72K 10-Q · filed 2023-11-13 | $182.28K derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $29.54K 10-Q · filed 2023-08-10 | $41.10K 10-Q · filed 2023-08-10 | $68.67K derived: sum of 3 quarters · filed 2023-08-10 | $102.14K derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $11.56K 10-Q · filed 2023-05-10 | $39.13K derived: sum of 2 quarters · filed 2023-05-10 | $72.60K derived: sum of 3 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $27.56K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $61.03K derived: sum of 2 quarters · filed 2023-03-27 | $139.00K 10-K · filed 2023-03-27 | ||||
| 2021-09-30 | $33.47K 10-Q · filed 2022-11-10 | $111.44K 10-Q · filed 2022-11-10 | |||||
| 2020-12-31 | $1.50M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| EDAP TMS SA (FOCL) | $0.171B | ||
| IRIDEX CORP (IRIX) | United States | $0.011B |